愛美醫療 FOLD 深 滬
等待開盤 11-04 09:30:00 美东时间
8.86
-0.170
-1.88%
華盛通- 最 高9.08
- 今 開9.01
- 成交量 762.73万股
- 最 低 8.62
- 昨 收 9.03
- 總市值 27.29亿
- 52周最高 11.14
- 市盈率 靜 --
- 換手率 2.48%
- 52周最低 5.51
- 委 比 68.49%
- 總股本 3.08亿
- 歷史最高 25.39
- 量 比 1.51
- 振 幅 5.09%
- 歷史最低 1.765
- 每 手 1
- 風險率 1.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
Amicus Therapeutics announced that its management will participate in two upcoming investor conferences in November. They will present at the 2025 UBS Global Healthcare Conference in Palm Beach Gardens, FL, on November 10, and the Jefferies Global Healthcare Conference in London, UK, on November 18. A live audio webcast of each presentation will be available via the investors section of the Amicus Therapeutics corporate website at [link]. Amicus ...
10-31 11:00
Fold To Release Third Quarter 2025 Results November 10th
Fold Holdings Inc., a bitcoin financial services company, will host its third-quarter earnings conference call on November 10, 2025, at 5:00 PM Eastern Time. Participants can join via live webcast or by dialing in after registering through the provided links. The call details, including dial-in number and passcode, will be emailed upon registration. Fold, known for its innovative bitcoin financial tools, is at the forefront of integrating bitcoin...
10-27 12:30
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-18 19:23
Needham Upgrades Amicus Therapeutics to Buy, Announces $14 Price Target
Needham analyst Gil Blum upgrades Amicus Therapeutics (NASDAQ:FOLD) from Hold to Buy and announces $14 price target.
09-18 18:00
Amicus Therapeutics Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
09-18 17:57
Analysts Offer Insights on Healthcare Companies: Amicus (FOLD) and Protara Therapeutics (TARA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-17 16:50
Amicus Therapeutics Reports 4-Year Muscle Function And Biomarker Data From PROPEL Study Of Cipaglucosidase Alfa + Miglustat In Late-Onset Pompe Disease
Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of cipaglucosidase alfa-atga +
09-08 21:05
仅一名员工，融资5.4亿
“核药”站上了风口。 作者丨王满华 来源丨投中网 一家创业公司想要获得上亿融资，其团队规模的下限是多少？来自挪威的Actithera给出了答案：一名员工足...
08-12 15:00
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /PRNewswire/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, partic...
08-06 20:30
